New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Tumor volume and CP score were top predictors of OS, along with liver gross tumor volume, functional liver volume V20, and prior liver-directed therapy.

Blocking a key metabolic enzyme helps B cells fight liver tumors, revealing a new immunotherapy pathway for fatty liver–driven cancer in mice.